Accession Number:

AD1035527

Title:

Killing MRSA in Wounds

Descriptive Note:

Technical Report,01 Jul 2010,30 Jun 2013

Corporate Author:

Rockefeller University New York United States

Personal Author(s):

Report Date:

2013-07-01

Pagination or Media Count:

20.0

Abstract:

Military personnel have an increased risk of injuries that would be susceptible to infection by Staphylococci MRSA. The approach uses the rapid killing action of a phage lysin that kills MRSA and all other staphylococci to treat MRSA-infected wounds in a rat model to prevent infection. It is anticipated that the lysin may be used in the field to eliminate MRSA during transport to the field hospital and after. We asked if combination therapy with lysin and vancomycin will be more effective in clearing MRSA from freshly contaminated wounds than the standard of care using vancomycin alone. Results show that wounds of rats treated with buffer alone exhibited 106 CFUgram of tissue of MRSA while animals treated with both Vancomycin lysin had an average of 102 CFUgram of tissue, a reduction of 4-logs of MRSA. Treatment with vancomycinbuffer or bufferlysin resulted in a total of 105. Experiments in which a combination of vancomycin and lysin was used on established MRSA wound infections, i.e., 5-dayabscesses, show that rats treated with buffer alone exhibited an average of 105 CFUgram of tissue of MRSA while animals treated with vancomycin and lysin had an average of 102 CFUgram of tissue, a reduction of 3-logs of MRSA. Treatment with vancomycinbuffer or bufferlysin resulted in a total of 103 CFUgm, reductions of 3 logs.

Subject Categories:

  • Medicine and Medical Research
  • Microbiology

Distribution Statement:

APPROVED FOR PUBLIC RELEASE